Breast cancer is the most widespread cancer in women accounting for almost a third of all new cancer cases among women in Western countries(1, 2). Whereas most breast cancers express hormone receptors, primarily estrogen receptors (ER), 2 and depend on these hormones for their growth, an estimated 15-20% of all cases harbor the triple-negative (estrogen receptor/progesterone receptor/epidermal growth factor receptor 2-negative) phenotype (3, 4). Although breast cancer tumors are widely heterogeneous, the presence or absence of estrogen receptors on breast tumor cells represents one of the main criteria used for prognosis and for choice of hormonal and chemotherapeutic drugs.Store-operated calcium (Ca 2ϩ ) entry (SOCE) is a ubiquitous pathway necessary for refilling internal Ca 2ϩ stores and for signaling downstream to the nucleus(5-9). SOCE have been implicated in many cell functions such as proliferation, migration, and differentiation (5, 10 -12). However, a thorough characterization of the SOCE pathway in estrogen receptor-positive (ER ϩ ) and negative (ER Ϫ ) breast cancer cells is so far missing. Upon store depletion, the Ca 2ϩ sensor STIM1, that resides in the endoplasmic reticulum, oligomerizes and translocates to subplasmalemmal puncta (13,14) where it activate Orai1 channels located in the plasma membrane that mediate highly Ca 2ϩ -selective currents(15-17). Mammals possess three Orai proteins (Orai1/2/3) (15); Orai1 and Orai3 are highly expressed in similar tissues including liver, lymphoid organs, skin, and skeletal muscle (18,19). However, Orai2 is mainly found in lung, brain, spleen, and kidney (20, 21). Orai1 proteins were shown to encode the archetypical SOCE current called Ca 2ϩ release-activated Ca 2ϩ current (I CRAC )(15, 22); I CRAC was first recorded by Hoth and Penner in RBL mast cells(23). Since their discovery three years ago, Orai1, along with STIM1, were shown to be the predominant contributors to SOCE in many cell types, including T cells, B cells, mast cells, platelets, endothelial cells, smooth muscle cells, microglia, human embryonic kidney cells (HEK293), hepatocytes, and oocytes (10, 11, 15, 18, 19, 22, 24 -28). However, the role of Orai2 and Orai3 in mediating native SOCE pathways and CRAC currents remain unknown. Here we show the first evidence for I CRAC in breast cancer cells and for a native SOCE/I CRAC pathway mediated by Orai3. We demonstrate that the SOCE pathway is mediated by STIM1/2 and Orai3 proteins in ER ϩ breast cancer cells whereas the canonical STIM1/Orai1 encodes the SOCE pathway in ER Ϫ breast cancer cells.
MATERIALS AND METHODSReagents-Thapsigargin, 2-APB, and nimodipine were purchased from Calbiochem, Fura-2AM was from Molecular Probes and GdCl 3 was from Acros Organics. Cs ϩ BAPTA and Pluronic F-127 were from Invitrogen. siRNAs were purchased from Dharmacon (see supplemental Table S2 for sequences). All the cell lines were bought from ATCC. All primers were synthesized by Integrated DNA Technologies. The transfection kit (VCA-1003) was from Lonza. All other ch...